Trial Profile
An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 02 May 2019 Results of six-years long-term follow-up of Chinese patients (n=322) published in the BMC Gastroenterology.
- 20 Dec 2010 Actual end date changed from Oct 2009 to Nov 2009 as reported by ClinicalTrials.gov.
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.